Foster Victor Wealth Advisors LLC Has $10.37 Million Stake in Becton, Dickinson and Company $BDX

Key Points

• Foster Victor Wealth Advisors LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 23.5% in Q4 to 50,049 shares, valued at about $10.37 million.
• BDX reported Q results with $2.91 EPS (beating estimates) but revenue of $4.49 billion missed consensus; the company set FY2026 guidance at $12.35–$12.65 EPS, pays a $1.05 quarterly dividend (2.7% yield) and authorized a $10 million buyback.
• Analysts have cut price targets and the stock holds a consensus "Hold" rating with an average target of $189.92 (six Buys vs. eleven Holds).

Foster Victor Wealth Advisors LLC grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 23.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 50,049 shares of the medical instruments supplier's stock after acquiring an additional 9,526 shares during the quarter. Foster Victor Wealth Advisors LLC's holdings in Becton, Dickinson and Company were worth $10,366,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of BDX. Brighton Jones LLC increased its stake in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares during the period. Empowered Funds LLC increased its stake in shares of Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier's stock valued at $1,827,000 after buying an additional 1,354 shares during the period. United Bank increased its stake in shares of Becton, Dickinson and Company by 23.9% in the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier's stock valued at $887,000 after buying an additional 993 shares during the period. Marshall Wace LLP increased its stake in shares of Becton, Dickinson and Company by 365.1% in the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier's stock valued at $5,491,000 after buying an additional 25,022 shares during the period. Finally, NewEdge Advisors LLC increased its stake in shares of Becton, Dickinson and Company by 34.7% in the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier's stock valued at $4,048,000 after buying an additional 6,058 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Analyst Ratings Changes

BDX has been the subject of several recent research reports. Citigroup lowered their price objective on Becton, Dickinson and Company from $233.00 to $232.00 and set a "buy" rating for the company in a research note on Tuesday, February 10th. Jefferies Financial Group lowered their price objective on Becton, Dickinson and Company from $220.00 to $190.00 and set a "buy" rating for the company in a research note on Tuesday, February 10th. Piper Sandler reaffirmed a "neutral" rating and issued a $170.00 price objective (down from $205.00) on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Argus lowered their price objective on Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating for the company in a research note on Monday, March 23rd. Finally, Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a research report on Tuesday. Six analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $189.92.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company's stock, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 953 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director owned 36,763 shares in the company, valued at $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,713 shares of company stock valued at $536,881 in the last three months. Insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $155.72 on Wednesday. The company has a market capitalization of $44.34 billion, a PE ratio of 25.40, a P/E/G ratio of 11.06 and a beta of 0.29. The company has a 50 day simple moving average of $169.00 and a two-hundred day simple moving average of $184.98. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts' consensus estimates of $2.81 by $0.10. The business had revenue of $4.49 billion during the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company's revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th were given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, March 10th. Becton, Dickinson and Company's dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company declared that its board has initiated a share repurchase program on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's board believes its shares are undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.